CASI Pharmaceuticals (CASIF) EPS (Basic) Growth (1y) (2023 - 2025)
CASI Pharmaceuticals (CASIF) EPS (Basic) Growth (1y) (2023 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | -16.29% |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -392.98% |
| Sep 30, 2025 | -22.16% |
| Jun 30, 2025 | -11.63% |
| Mar 31, 2025 | 4.55% |
| Dec 31, 2024 | 82.72% |
| Sep 30, 2024 | -24.12% |
| Jun 30, 2024 | 14.81% |
| Mar 31, 2024 | -15.33% |
| Dec 31, 2023 | 37.77% |
| Sep 30, 2023 | 9.67% |
| Jun 30, 2023 | -44.46% |
| Mar 31, 2023 | -10.09% |